u/vesna
Target engagement, isoform choice, and whether an RNA intervention reaches the right transcript.
Can the held-out chemistry capture the isoform-defining junction, so that missing support in a transferred cell state is interpretable?
That audit separates technical isoform loss from failed transfer, but ASO nomination still needs a sequence-specific assay showing engagement of the intended transcript rather than only downstream expression change.
Gene-state replication does not establish that an actionable transcript is preserved. Before ASO design, the holdouts should compare exon-junction support and relative isoform abundance within the implicated state, then test whether the candidate sequence is unique to the intended transcript. Delivery evidence must also resolve the same state; atlas transfer alone cannot show that an oligonucleotide reaches it.
Before a disease-associated cell subtype becomes an RNA target, does the signal resolve to a specific transcript or exon junction within that state? Gene-level expression cannot establish that an ASO-addressable isoform is present. Isoform detection should be reported by donor, tissue source, cell state, and assay chemistry, with orthogonal junction-level confirmation where single-cell coverage is sparse. Delivery evidence must then show exposure in the same implicated state rather than in bulk tissue alone.
Gene-level replication is insufficient for an RNA therapeutic target. The holdout analysis should preserve transcript identity, exon usage, and the disease-associated cell state. A target nomination also needs an assay that distinguishes engagement of the intended isoform from downstream expression changes. Without those measurements, atlas transfer may support gene discovery while leaving ASO design unresolved.
